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Abstract : Glucagon-like peptide 1 receptor agonists （GLP-1RAs） have been 
shown to exert anti-atherosclerotic effects via multiple mechanisms on dif-
ferent types of cells.  However, it is unclear which of these mechanisms are 
crucial.  We investigated the role of vascular endothelial cells （VECs） in 
the anti-atherogenic effects of the GLP-1RA liraglutide in a mouse model 
of atherosclerosis.  Streptozotocin-induced diabetic apolipoprotein E-null mice 
were randomly assigned to treatment with either vehicle （saline） or liraglu-
tide （107 nmol/kg/day）, and were subjected to femoral artery wire injury to 
remove VECs.  After 4 weeks, vessel samples were collected for analysis.   
Streptozotocin-injected mice had fasting plasma glucose levels of ＞300 mg/dl and 
hemoglobin A1c levels of ＞ 9％, indicating that the injections had induced severe 
hyperglycemia.  However, there were no differences in metabolic characteristics 
such as levels of hemoglobin A1c, fasting plasma glucose, total cholesterol, and 
triglycerides between the vehicle and liraglutide groups.  Analysis of atherosclerotic 
plaque formation revealed that liraglutide treatment signicantly suppressed plaque 
formation in the aorta.  In addition, liraglutide treatment reduced plaque volume 
and intra-plaque macrophage accumulation at the aortic sinus.  Furthermore, 
liraglutide treatment suppressed vascular expression of pro-inammatory cytokines.  
In uninjured femoral arteries, no plaques were observed ; however, severe plaque 
formation occurred in femoral arteries that had been injured by wire insertion to 
remove VECs.  Unlike in the uninjured aorta, liraglutide treatment did not affect 
plaque volume or arterial remodeling （intimal and medial thinning, and arterial  
dilation） in wire-injured femoral arteries.  Of the various cells that liraglutide affects, 
VECs play a central role in liraglutide’s anti-atherogenic effects in diabetic mice.
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Introduction
　Glucagon-like peptide 1 （GLP-1） is a gut peptide hormone that is secreted from intestinal L 
Original
Department of Internal Medicine, Division of Diabetes, Metabolism and Endocrinology, Showa University School of 
Medicine, 1—5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
＊ To whom corresponding should be addressed.
Masakazu KOSHIBU, et al116
cells in response to digestion 1，2）.  In pancreatic β cells, which express GLP-1 receptors, GLP-1 
stimulates insulin secretion in a glucose concentration-dependent manner, which enables GLP-1 to 
induce potent glucose-lowering effects without increasing the risk of hypoglycemia.  In addition, 
GLP-1 exerts favorable metabolic effects such as reduction of body weight and amelioration 
of hypertriglyceridemia.  Due to the very short half-life of endogenous GLP-1, GLP-1 receptor 
agonists （GLP-1RAs） that are resistant to degradation have been developed and are widely used 
for the treatment of type 2 diabetes.
　In addition to pancreatic β cells, GLP-1 receptors are expressed in a variety of other cells, 
including cells in the cardiovascular system 3）.  Numerous preclinical studies have demonstrated 
that GLP-1 and GLP-1RAs exert direct anti-atherogenic effects in animal models, and they 
induce favorable changes against atherosclerosis in various cells such as vascular endothelial cells 
（VECs）, vascular smooth muscle cells （VSMCs）, and macrophages 4-10）.  Large-scale clinical trials 
have consistently demonstrated that treatment with GLP-1RAs reduces the incidence of adverse 
cardiovascular events compared with placebo in patients with type 2 diabetes11-13）.  Therefore, 
GLP-1RAs are recommended for the prevention of atherosclerotic cardiovascular disease in 
patients with type 2 diabetes 14）.  However, the underlying mechanisms of this benet are not yet 
fully understood.
　In the present study, we sought to determine the role of VECs in the anti-atherogenic effects 
of the GLP-1RA liraglutide by comparing atherosclerotic plaque formation in endothelium-intact 
and endothelium-denuded vessels of mice.
Materials and methods
Treatment of mice
　The study design was approved by the Animal Care Committee of Showa University School 
of Medicine （approval number : 07005）.  Six-week-old male apolipoprotein E-null （ApoE－/－） 
mice （BALB/c, KOR/StmSlc-Apoeshl） were purchased from Sankyo Labo Service （Tokyo, 
Japan）.  ApoE－/－ mice were maintained on standard rodent chow with free access to chow and 
water in a specic pathogen-free room in the Division of Animal Experimentation of Showa 
University School of Medicine.  Diabetes was induced by injecting streptozotocin （Sigma-Aldrich 
Japan, Tokyo, Japan） as previously reported 15, 16）.  Briey, ApoE－/－ mice received intra-peritoneal 
injections of streptozotocin at a dose of 100 mg/kg/day for ve consecutive days at 15 weeks of 
age, and additional injections at a dose of 50 mg/kg/day for ve consecutive days at 18 weeks of 
age.  At 20 weeks of age, development of diabetes was dened as random plasma glucose levels 
＞200 mg/dl, and diabetic mice were randomly assigned to one of two groups : treatment with 
vehicle （saline） or treatment with liraglutide （107 nmol/kg/day）4）.  Also, diet was switched at 
20 weeks from standard rodent chow to western diet （30％ fat and 0.15％ cholesterol ; Oriental 
Yeast, Tokyo, Japan）4，5，15，16）.  Liraglutide treatment was delivered by osmotic pumps that were 
implanted under the dorsal skin （mini pump model 1002 ; Alzet, Cupertino, CA, USA）.  Two 
days after treatment initiation, mice were subjected to left femoral artery wire injury to remove 
VECs from the lumen, as previously established by Sata et al 17）.  Briefly, a straight spring 
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guidewire was inserted into the femoral artery in a retrograde direction, via a small cut on the 
branch artery, and carefully withdrawn after 1 minute.  After 4 weeks of treatment, mice were 
euthanized by isourane overdose, and blood and vessel samples were collected.
Assessment of plasma glucose, HbA1c and lipid levels
　Blood samples were collected from the inferior vena cava after 6 hours of fasting.  Plasma 
glucose levels were measured using a dextrometer （Glutest Sensor NeoSuper, Sanwa Kagaku, 
Aichi, Japan）.  Hemoglobin A1c （HbA1c） levels were determined using a latex-enhanced immu-
noassay and plasma lipid levels were determined using an enzymatic colorimetric assay, both 
performed using a Cobas analyzer （Roche Diagnostics Japan, Tokyo, Japan）.
Blood pressure and pulse rate measurements
　Blood pressure and pulse rate were measured using the tail-cuff method, as previously 
described （Model MK-2000ST ; Muromachi Kikai, Tokyo, Japan）18）.
Assessment of atherosclerosis
　The aortas and femoral arteries were carefully removed from surrounding connective tissue. 
Atherosclerotic plaque formation was evaluated as previously described 4, 5, 15, 16）.  Briey, cryosec-
tions of the aortic sinus and femoral artery were stained with Elastica van Gieson and/or oil 
red O.  The aorta was longitudinally dissected and stained with oil red O.  Assessment of ath-
erosclerosis was conducted by an investigator blinded to the treatment, using Image J software 
（National Institutes of Health, Bethesda, MD, USA）.
Assessment of intra-plaque macrophage accumulation
　Intra-plaque macrophage accumulation was assessed in cryosections of the aortic sinus by 
immunohistochemistry, using anti-MOMA2 antibody （1 : 60 ; RRID, AB_776518 ; Catalogue ID, 
ab33451 ; Abcam Japan, Tokyo, Japan）4, 5）.
Assessment of gene expression
　Total RNA was extracted from the brachiocephalic arteries using Isogen （Nippon Gene, Tokyo, 
Japan）, and used to synthesize cDNA using ReverTra Ace （Toyobo, Osaka, Japan） as previously 
described 18）.  Gene expression was assessed by real-time reverse transcription PCR using the 
TaqMan gene expression assay and a sequence detection system （StepOne ; Life Technologies 
Japan, Tokyo, Japan）.  The following pre-designed TaqMan probe sets were used : interleukin-1β 
（IL-1β）, Mm00434228 m1 ; IL-6, Mm00446190 m1 ; monocyte chemoattractant protein-1 （Mcp-1）, 
Mm00441242 m1 ; tumor necrosis factor α （TNFα）, Mm00443258 m1 ; 18S ribosomal RNA 
（18sRNA）, Mm03928990 g 1）.
Statistical analysis
　Comparisons were conducted using an unpaired t-test with JMP software （version 13 ; SAS 
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Institute Inc., Cary, NC, USA）.  Signicance was dened as p＜0.05.
Results
Characteristics of the two groups were similar
　The physiological and biochemical characteristics of diabetic mice treated with vehicle and 
those treated with liraglutide are shown in Table 1.  Vehicle-treated mice had fasting plasma 
glucose levels of ＞300 mg/dl and HbA1c levels of ＞9％, indicating that the streptozotocin 
injections had induced severe hyperglycemia.  However, there were no differences in physiological 
or biochemical characteristics, including fasting plasma glucose and HbA1c levels, between the 
vehicle-treated and liraglutide-treated groups.
Liraglutide treatment suppressed atherosclerotic plaque formation
　Assessment of atherosclerosis in the aortas of the diabetic mice revealed that liraglutide treat-
ment signicantly reduced atherosclerotic plaque area as determined by oil red O staining on 
the aortic surface （Fig. 1A and D）.  Consistent with this nding, liraglutide treatment reduced 
atherosclerotic plaque volume measured at the aortic sinus （Fig. 1B and E）.  Furthermore, 
liraglutide treatment decreased intra-plaque macrophage accumulation, which is involved in ath-
erosclerotic plaque progression and rupture （Fig. 1C and F）19, 20）.
Liraglutide treatment reduced pro-inammatory cytokine expression
　The effects of liraglutide on vascular inammation, which plays an essential role in athero-
sclerotic plaque formation 21）, were examined next.  Pro-inflammatory cytokine expression was 
assessed in the brachiocephalic arteries, sites that are prone to atherosclerosis22）.  Liraglutide 
treatment signicantly reduced expression of IL-1β, IL-6, and Mcp-1 （Fig. 2A-C）, and resulted 
in a non-signicant reduction in TNFα expression （p＝0.15, Fig. 2D）.
Table 1.   Physiological and biochemical characteristics of diabetic 
ApoE－/－ mice treated with vehicle or liraglutide＊
Vehicle （n＝9） Liraglutide （n＝6）
Food intake （g/day）  3.8±0.2  3.7±0.3
Water intake （g/day） 16.5±1.4 20.0±1.1
Final body weight （g） 21.8±1.5 24.4±1.2
Pulse rate （beats/min） 642±7 619±13
Systolic BP （mmHg）  120±5 123±7
Plasma glucose （mg/dl）  345±41 383±24
Hemoglobin A1c （％）  9.1±0.9     9.1±0.3
Total cholesterol （mg/dl） 494±59 502±62
Triglycerides （mg/dl） 298±81 292±82
HDL-C （mg/dl） 71±6 63±3
＊Values are mean±standard error of mean.  
 BP, blood pressure ; HDL-C, high-density lipoprotein cholesterol.
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Anti-atherogenic effects of liraglutide were compromised by VEC removal
　The role of VECs in the anti-atherogenic effects of liraglutide was examined by removing 
VECs from the left femoral artery lumen by inserting a guidewire.  After 4 weeks, atheroscle-
Fig. 1.  Liraglutide treatment suppresses atherosclerotic plaque formation in diabetic ApoE －/－ mice
Streptozotocin-induced diabetic mice were treated with vehicle or liraglutide for 4 weeks, and their aortas were 
collected for analysis of atherosclerosis. （A） Representative microscopic images of aortas stained with oil red O. 
White arrows indicate atherosclerotic plaques. （B, C） Representative images of the aortic sinus with oil red O staining 
and MOMA-2 immunostaining, respectively. Black arrows and arrowheads indicate atherosclerotic plaques and intra-
plaque macrophage accumulation, respectively. Scale bars, 250 µm. （D） Atherosclerotic plaque area on the aortic 
surface （＊p＜0.05）. （E, F） Atherosclerotic plaque volume and intra-plaque macrophage accumulation, respectively, at 
the aortic sinus （＊p＜0.05）. Graphed values are means, and each error bar indicates standard error of mean.
Masakazu KOSHIBU, et al120
rotic lesions, accompanied by arterial remodeling （intimal and medial hyperplasia, and arterial 
dilation）, formed in the wire-inserted left femoral arteries （Fig. 3A-E）, whereas such changes 
were not observed in uninjured right femoral arteries.  However, in contrast to our ndings in 
uninjured aortas, liraglutide did not affect atherosclerotic lesion formation or arterial remodeling 
in wire-injured left femoral arteries （Fig. 3A-E）.
Discussion
　In the present study, we demonstrated that liraglutide treatment suppressed atherosclerotic 
plaque formation in the aortas of mice.  However, the anti-atherogenic effects of liraglutide were 
not observed in femoral arteries in which VECs had been removed from the lumen surface 
by insertion of a guidewire.  In the segment where a guidewire is inserted, VECs are almost 
completely removed by mechanical stress 17, 23）.  Previous studies, including studies that we have 
conducted, have demonstrated anti-atherogenic effects of GLP-1 and GLP-1RAs in animal mod-
els 4-10）, but these did not determine whether GLP-1RA treatment suppresses atherosclerosis in 
the femoral artery after wire injury.  Our ndings from the present study indicate that the anti-
atherogenic effects of liraglutide are compromised by the removal of VECs.
　Previous studies have demonstrated that GLP-1RAs induce anti-atherogenic changes in VECs, 
such as enhancement of nitric oxide （NO） production and suppression of cell adhesion molecule 
expression 5，7，18，24）.  Extensive research has shown the importance of NO not only in maintain-
ing normal vessel conditions but also in preventing atherosclerosis and vascular remodeling 25, 26）. 
NO exerts multiple actions in various cells that are involved in the process of atherosclerotic 
Fig. 2.  Liraglutide suppresses expression of pro-inflammatory cytokines in the brachiocephalic artery
Streptozotocin-induced diabetic mice were treated with vehicle or liraglutide for 4 weeks, and their brachiocephalic 
arteries were collected for analysis of pro-inflammatory cytokine expression by real time reverse transcription PCR. 
（A-D） IL-1β, IL-6, TNFα, and Mcp-1 expression levels, respectively. Target gene expression was normalized to that 
of the housekeeping gene 18sRNA （＊p＜0.05）. Graphed values are means, and each error bar indicates standard error 
of mean.
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plaque formation.  For example, in VECs, NO prevents expression of pro-inammatory cytokines 
and cell adhesion molecules via suppression of transcription factors （eg, nuclear factor κB） 
and oxidative stress 27，28）.  Also, NO inhibits proliferation and migration of VSMCs ̶ processes 
that contribute to the development of atherosclerotic plaques 29）.  We previously reported that 
liraglutide treatment increases NO levels in plasma and phosphorylated endothelial NO synthase 
levels in the aorta 18）.  In addition, liraglutide treatment suppresses peripheral arterial remodeling 
in mouse models, and this effect is completely abolished by inhibiting NO synthase.  These nd-
Fig. 3.  Anti-atherogenic effects of liraglutide are compromised by removal of VECs
Streptozotocin-induced diabetic mice were treated with vehicle or liraglutide for 4 weeks, VECs were removed from 
the lumen surface of their left femoral arteries by wire injury （2 days after treatment initiation）, and both femoral 
arteries were collected for analysis of atherosclerosis. （A） Representative images of the femoral arteries were stained 
with oil red O （upper panels） and Elastica van Gieson （lower panels）. Scale bars, 100 µm. （B） Atherosclerotic plaque 
volume. （C） Intimal area. （D） Medial area. （E） Arterial perimeter.  Graphed values are means, and each error bar 
indicates standard error of mean. ORO, oil red O.
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ings indicate that enhancement of NO production in VECs is a possible mechanism of the VEC-
dependent anti-atherogenic effects of liraglutide.
　Previous studies employing non-diabetic animals have shown that GLP-1 and GLP-1RAs sup-
press phenotypic changes and inammatory responses in macrophages 5，7，30）, which are involved in 
atherosclerotic plaque progression 19，20）.  Consistent with these ndings, we found that liraglutide 
treatment suppressed intra-plaque macrophage accumulation and reduced vascular expression of 
pro-inammatory cytokines in diabetic mice, suggesting that anti-inammatory effects of liraglutide 
are preserved under hyperglycemic conditions.  However, liraglutide treatment failed to suppress 
atherosclerosis formation in arteries in which VECs had been removed.  These ndings imply 
that the anti-inammatory effects of liraglutide are not the main mechanisms by which liraglutide 
suppresses atherosclerosis.
　The present study has several limitations.  First, anti-atherogenic effects of liraglutide were com-
pared in different vessels ― endothelium-intact aortas and endothelium-denuded femoral arteries. 
As shown in Fig. 3A, atherosclerotic plaque is rarely formed in uninjured femoral arteries, which 
makes it difcult to directly compare the anti-atherogenic effects of liraglutide between uninjured 
and injured arteries.  In addition, removal of VECs from the aorta is technically challenging in 
mice.  Thus, the role of VECs in the anti-atherogenic effects of liraglutide needs to be further 
evaluated in bilateral arteries of larger animals such as rabbits or pigs 31）.  For example, more 
robust conclusions could be obtained by comparing the anti-atherogenic effects of GLP-1RA in 
the left and right iliac arteries of cholesterol-fed rabbits following unilateral arterial injury.
　In conclusion, although liraglutide has multiple effects on various cells, our data show that 
VECs are essential for liraglutide to suppress atherosclerosis in diabetic ApoE－/－ mice.
Conict of interest disclosure
　T.H. has received lecture fees from AstraZeneca, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, 
MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, and Takeda.  All other authors declare that they 
have no competing interests.  This study was not financially supported by any institution.
References
1） Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efcacy and safety of glucagon-like peptide-1 receptor agonists in 
type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524-
536.
2） Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 
2013;62:3316-3323.
3） Pujadas G, Drucker DJ. Vascular biology of glucagon receptor superfamily peptides: mechanistic and clinical rel-
evance. Endocr Rev. 2016;37:554-583.
4） Tashiro Y, Sato K, Watanabe T, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell 
formation and atherosclerosis. Peptides. 2014;54:19-26.
5） Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions 
in apolipoprotein E knockout mice. Diabetologia. 2011;54:2649-2659.
6） Bisgaard LS, Bosteen MH, Fink LN, et al. Liraglutide reduces both atherosclerosis and kidney inammation in 
123Anti-atherogenic Effects of Liraglutide
moderately uremic LDLr-/- mice. PLoS One. 2016;11:e0168396. （accessed 2019 Nov 22） Available from: https://
journals.plos.org/plosone/article?id=10.1371/journal.pone.0168396
7） Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of 
atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59:1030-1037.
8） Jojima T, Uchida K, Akimoto K, et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell 
proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in 
ApoE decient mice. Atherosclerosis. 2017;261:44-51.
9） Gaspari T, Welungoda I, Widdop RE, et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular 
disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE（-/-） mouse model. Diab 
Vasc Dis Res. 2013;10:353-360.
10） Wang Y, Parlevliet ET, Geerling JJ, et al. Exendin-4 decreases liver inammation and atherosclerosis development 
simultaneously by reducing macrophage inltration. Br J Pharmacol. 2014;171:723-734.
11） Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N 
Engl J Med. 2016;375:311-322.
12） Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N 
Engl J Med. 2016;375:1834-1844.
13） Hernandez AF, Green JB, Janmohamed S, et al. Harmony Outcomes committees and investigators. Albiglutide 
and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease （Harmony Outcomes）: a 
double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519-1529.
14） Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus 
report by the American Diabetes Association （ADA） and the European Association for the Study of Diabetes 
（EASD）. Diabetes Care. 2018;41:2669-2701.
15） Terasaki M, Hiromura M, Mori Y, et al. Combination therapy with a sodium-glucose cotransporter 2 inhibitor 
and a dipeptidyl peptidase-4 inhibitor additively suppresses macrophage foam cell formation and atherosclerosis 
in diabetic mice. Int J Endocrinol. 2017;2017:1365209. （accessed 2019 Nov 22） Available from: https://www.hindawi.
com/journals/ije/2017/1365209/
16） Terasaki M, Hiromura M, Mori Y, et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 
inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 
1 and type 2 diabetic mice. PLoS One. 2015;10:e0143396. （accessed 2019 Nov 22） Available from: https://journals.
plos.org/plosone/article?id=10.1371/journal.pone.0143396
17） Sata M, Maejima Y, Adachi F, et al. A mouse model of vascular injury that induces rapid onset of medial cell 
apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000;32:2097-2104.
18） Kushima H, Mori Y, Koshibu M, et al. The role of endothelial nitric oxide in the anti-restenotic effects of lira-
glutide in a mouse model of restenosis. Cardiovasc Diabetol. 2017;16:122. （accessed 2019 Nov 22） Available from: 
https://cardiab.biomedcentral.com/articles/10.1186/s12933-017-0603-x
19） Gerrity RG. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in 
fatty lesions. Am J Pathol. 1981;103:181-190.
20） Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
21） Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger rm adhesion of monocytes to vascular 
endothelium under ow conditions. Nature. 1999;398:718-723.
22） Li Y, Zhang CG, Wang XH, et al. Progression of atherosclerosis in ApoE-knockout mice fed on a high-fat diet. 
Eur Rev Med Pharmacol Sci. 2016;20:3863-3867.
23） Mori Y, Kushima H, Koshibu M, et al. Glucose-dependent insulinotropic polypeptide suppresses peripheral arterial 
remodeling in male mice. Endocrinology. 2018;159:2717-2732.
24） Krasner NM, Ido Y, Ruderman NB, et al. Glucagon-like peptide-1 （GLP-1） analog liraglutide inhibits endothelial 
Masakazu KOSHIBU, et al124
cell inammation through a calcium and AMPK dependent mechanism. PLoS One. 2014;9:e97554. （accessed 2019 
Nov 22） Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0097554
25） Sukhovershin RA, Yepuri G, Ghebremariam YT. Endothelium-derived nitric oxide as an antiatherogenic mecha-
nism: implications for therapy. Methodist Debakey Cardiovasc J. 2015;11:166-171.
26） Otsuka F, Finn AV, Yazdani SK, et al. The importance of the endothelium in atherothrombosis and coronary stent-
ing. Nat Rev Cardiol. 2012;9:439-453.
27） De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric 
oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin 
Invest. 1995;96:60-68.
28） Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutro-
phil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992;90:1116-1121.
29） Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118:692-702.
30） Bruen R, Curley S, Kajani S, et al. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice dur-
ing early atherosclerosis. Cardiovasc Diabetol. 2017;16:143. （accessed 2019 Nov 22） Available from: https://cardiab.
biomedcentral.com/articles/10.1186/s12933-017-0626-3
31） Touchard AG, Schwartz RS. Preclinical restenosis models: challenges and successes. Toxicol Pathol. 2006;34:11-18.
［Received December 7, 2018 : Accepted December 25, 2018］ 
